Remarkably, the quantification of β-ARs in patient-derived cells and tissues highlighted that of the three β-AR receptors, the β2 subtype was strongly expressed in SFT and liposarcoma cells, which responded better to the combination of propranolol with docetaxel. The gene discussed is CTBP1; the disease is liposarcoma.